Home / Companies / Travere Therapeutics, Inc. / 15 May 2025
Travere Therapeutics, Inc.: meeting of 15 May 2025
Votes reported on Form N-PX, item by item
324 Form N-PX filers reported votes at the Travere Therapeutics, Inc. meeting of 15 May 2025. Their records fall into 4 items below, in ballot order: management items first, then proposals from security holders. Each bar shows how the reporting filers split; it is not the result of the meeting.
foragainstabstain, withhold or otheramber tick: the portion cast against management
Items
DIRECTOR ELECTIONSIssuer
Director elections
10 nominees; 98.7% of reported votes for; 9 filers withheld from or voted against at least one nominee.
2,080 vote records from 117 filers. 1 of the 117 filers that marked the item either way voted against management.
SECTION 14A SAY-ON-PAY VOTESIssuer
Advisory vote on executive pay (say-on-pay)
484 vote records from 321 filers. 15 of the 310 filers that marked the item either way voted against management. 11 filers reported this item without a management mark.
AUDIT-RELATEDIssuer
Audit-related items (auditor ratification)
208 vote records from 117 filers. 1 of the 117 filers that marked the item either way voted against management.
COMPENSATIONIssuer
COMPENSATION: management items
Management items in this category are shown together; filers word and number them differently.
212 vote records from 118 filers. 5 of the 118 filers that marked the item either way voted against management.
How the largest families voted
* against management. A family's position is the way most of its reported shares were voted across its filers; "split" means no single position led. "No report" means none of the family's filers listed the item.
Questions
How did large funds vote at the Travere Therapeutics, Inc. meeting?
324 Form N-PX filers reported votes at the meeting of 15 May 2025. On say-on-pay, 15 of 310 voted against management (4.8%). The family table lists each of the largest families item by item.
Is this the meeting result?
No. These are the votes of funds and managers that file Form N-PX, counted by filer and by the shares they reported. The certified result, which includes every shareholder, is reported by Travere Therapeutics, Inc. on Form 8-K.
Why are director elections shown as counts only?
Director records name the nominee. This site does not publish pages or rows about individuals, so for director elections it keeps the number of nominees and the split of votes and discards the wording.
Every meeting on file for Travere Therapeutics, Inc.
Provenance: SEC EDGAR, Form N-PX and N-PX/A filings listing Travere Therapeutics, Inc. with a meeting date within three days of 15 May 2025. Proposal titles are the most common wording among filers and are replaced by the SEC category where a wording could name a person. Not verified by the SEC. Filings read through 23 Sep 2026.